• 1. Dissolution of cork biopolymers in biocompatible ionic liquids
  Helga Garcia,Rui Ferreira,Marija Petkovic,Jamie L. Ferguson,Maria C. Leit?o,H. Q. Nimal Gunaratne,Luís Paulo N. Rebelo Green Chem., 2010,12, 367-369
• 2. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 3. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 4. Fe3O4 nanoclusters highly dispersed on a porous graphene support as an additive for improving the hydrogen storage properties of LiBH4?
  Guang Xu,Wei Zhang,Ying Zhang,Xiaoxia Zhao,Ping Wen,Di Ma RSC Adv., 2018,8, 19353-19361
• 5. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789

Recent Advances in the Application of 5-(Trifluoromethyl)-3-pyridinylboronic Acid Hydrochloride (CAS: 1003298-83-6) in Chemical Biology and Pharmaceutical Research

The compound 5-(trifluoromethyl)-3-pyridinylboronic acid hydrochloride (CAS: 1003298-83-6) has garnered significant attention in recent years due to its versatile applications in chemical biology and pharmaceutical research. This boronic acid derivative is particularly valued for its role in Suzuki-Miyaura cross-coupling reactions, a cornerstone in the synthesis of complex organic molecules, including pharmaceuticals. Recent studies have highlighted its utility in the development of novel therapeutic agents, especially in the fields of oncology and infectious diseases.

One of the most notable applications of 5-(trifluoromethyl)-3-pyridinylboronic acid hydrochloride is in the synthesis of kinase inhibitors. Kinases are critical targets in cancer therapy, and the trifluoromethyl group on the pyridine ring enhances the binding affinity and selectivity of these inhibitors. A 2023 study published in the Journal of Medicinal Chemistry demonstrated the compound's efficacy in the synthesis of a new class of EGFR inhibitors, showing promising results in preclinical models of non-small cell lung cancer (NSCLC). The study reported a significant reduction in tumor growth and improved survival rates in animal models.

In addition to its role in oncology, this boronic acid derivative has been explored for its potential in antimicrobial drug development. Researchers have utilized it to synthesize novel boron-containing antibiotics that target resistant bacterial strains. A recent publication in Bioorganic & Medicinal Chemistry Letters detailed the compound's use in creating analogs of existing antibiotics, which exhibited enhanced activity against methicillin-resistant Staphylococcus aureus (MRSA). The incorporation of the trifluoromethyl group was found to improve the compounds' metabolic stability and bioavailability.

The chemical properties of 5-(trifluoromethyl)-3-pyridinylboronic acid hydrochloride also make it a valuable tool in proteomics and chemical biology. Its ability to form stable complexes with diols and other functional groups has been leveraged in the development of boronic acid-based probes for detecting and quantifying biomolecules. A 2022 study in Analytical Chemistry showcased its use in a fluorescence-based assay for glucose detection, offering a potential alternative to traditional enzymatic methods. This application could have significant implications for diabetes management and diagnostics.

Despite its promising applications, challenges remain in the large-scale synthesis and purification of 5-(trifluoromethyl)-3-pyridinylboronic acid hydrochloride. Recent advancements in flow chemistry and continuous manufacturing have addressed some of these issues, as reported in a 2023 article in Organic Process Research & Development. The study highlighted improved yields and reduced reaction times using these innovative techniques, paving the way for more efficient production processes.

In conclusion, 5-(trifluoromethyl)-3-pyridinylboronic acid hydrochloride (CAS: 1003298-83-6) continues to be a pivotal compound in chemical biology and pharmaceutical research. Its diverse applications, from drug synthesis to biomolecular detection, underscore its importance in advancing scientific and medical knowledge. Future research is expected to further explore its potential, particularly in addressing unmet medical needs and improving therapeutic outcomes.

• 1692-25-7(Pyridin-3-ylboronic acid)
• 1423-26-3([3-(trifluoromethyl)phenyl]boronic acid)
• 73852-19-4(3,5-Bis(trifluoromethyl)phenylboronic acid)
• 173999-18-3((5-methylpyridin-3-yl)boronic acid)
• 196083-18-8((2,5-bis(trifluoromethyl)phenyl)boronic acid)
• 387824-61-5(3-(trifluoromethyl)pyridin-4-amine)
• 3796-23-4(3-(Trifluoromethyl)pyridine)
• 148546-82-1(4-Methylpyridine-3-boronic Acid)
• 128796-39-4([4-(trifluoromethyl)phenyl]boronic acid)
• 364590-93-2((4'-(Trifluoromethyl)-[1,1'-biphenyl]-4-yl)boronic acid)